Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice-Reference-Cited by-同舟云学术

Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice

Published:2021-03 Issue: Volume:Volume 14 Page:963-981
ISSN:1178-7007
Container-title:Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
language:en
Short-container-title:DMSO

Author:

Feng Li,Wang Songhua,Chen Feng,Zhang Cheng,Wang Qiao,Zhao Yuting,Zhang Zifeng

Publisher

Informa UK Limited

Subject

Pharmacology,Internal Medicine

Reference58 articles.

1. Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy

2. Endothelin: 30 Years From Discovery to Therapy

3. Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?

4. Endothelin‐1 in the pathophysiology of obesity and insulin resistance

5. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic underpinnings of cancer-related fatigue;American Journal of Physiology-Endocrinology and Metabolism;2024-03-01

2. The p66Shc Redox Protein and the Emerging Complications of Diabetes;International Journal of Molecular Sciences;2023-12-20

3. Mitochondrial Cristae Morphology Reflecting Metabolism, Superoxide Formation, Redox Homeostasis, and Pathology;Antioxidants & Redox Signaling;2023-10-01

4. PRKCD as a potential therapeutic target for chronic obstructive pulmonary disease;International Immunopharmacology;2022-12

5. Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium;Cardiovascular Diabetology;2022-06-09